This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
After Golden Cross, Coterra Energy (CTRA)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
CTRANegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, USA Compression Partners (USAC)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
USACNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales
by Zacks Equity Research
Madrigal stock slides 10% as the preliminary Q4 Rezdiffra sales figures failed to impress investors.
BMRNNegative Net Change CTMXNegative Net Change MDGLNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines
by Zacks Equity Research
Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines have been highlighted in this Industry Outlook article.
BMRNNegative Net Change INCYPositive Net Change EXELNegative Net Change HALOPositive Net Change
biotechnology
Regeneron Reports Eylea Sales, Provides Other Pipeline Updates
by Zacks Equity Research
REGN announces business updates at the J.P. Morgan Healthcare Conference. The company also reports sales for Eylea and Eylea HD (on a preliminary basis).
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy
by Zacks Equity Research
BPMC stock rallies 18% on the company's optimistic 2025 outlook encompassing Ayvakit sales growth and pipeline progress.
HALOPositive Net Change CTMXNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
5 Biotech Stocks Worth Adding to Your Portfolio in 2025
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid pipeline progress position INCY, BMRN, EXEL, HALO and BPMC well in this volatile sector.
INCYPositive Net Change BMRNNegative Net Change EXELNegative Net Change HALOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Plains All American Pipeline (PAA) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
PAANegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales
by Zacks Equity Research
Pacira stock gains 11% on better-than-expected preliminary Q4 sales figures. It also shares a strategic growth plan to drive innovation and value creation by 2030.
HALOPositive Net Change PCRXNegative Net Change CTMXNegative Net Change CSTLPositive Net Change
biofuels biotechnology medical pharmaceuticals
ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz
by Zacks Equity Research
Intra-Cellular stock gains 15% as it settles Caplyta patent litigation with Sandoz protecting the drug's exclusivity in the United States till July 1, 2040.
CTMXNegative Net Change CSTLPositive Net Change SDZNYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Exelixis Provides Preliminary 2024 Results and Outlook for 2025
by Zacks Equity Research
EXEL reports preliminary 2024 revenues. The company also provides guidance for 2025 and other pipeline updates.
BMYNegative Net Change MRKPositive Net Change EXELNegative Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?
by Ekta Bagri
REGN's Eylea faces a rapid decline in sales, impacting overall performance even though Dupixent maintains momentum. We advise investors to stay on the sidelines for now.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change AMGNPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib
by Zacks Equity Research
EXEL's sNDA seeking approval of cabozantinib for the treatment of pancreatic neuroendocrine tumors will not be discussed at an ODAC.
MRKPositive Net Change EXELNegative Net Change CSTLPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock?
by Zacks Equity Research
ADMA Biologics performance in the past twelve months has been phenomenal. While the prospects remain sound, the exceptional rally witnessed by the stock might limit any further gain.
GRFSPositive Net Change ADMANegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data
by Zacks Equity Research
Sana stock soars in a week following positive initial data from a first-in-human study of investigational cell therapy, UP421, in diabetes patients.
HALOPositive Net Change CTMXNegative Net Change CSTLPositive Net Change SANAPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More
by Zacks Equity Research
NMRA and HOTH are in the spotlight in the biotech sector on study data announcement.
TEVAPositive Net Change CPRXNegative Net Change HOTHNegative Net Change VIRNegative Net Change NMRAPositive Net Change
biotechnology biotechs medical pharmaceuticals
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation
by Zacks Equity Research
Denali obtains Breakthrough Therapy Designation for its experimental candidate, tividenofusp alfa (DNL310), for the treatment of pateints with Hunter syndrome.
SNYPositive Net Change BIIBNegative Net Change HALOPositive Net Change DNLINegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy
by Zacks Equity Research
Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand recognition of Ozempic and Wegovy.
NVOPositive Net Change LLYPositive Net Change HALOPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Arc Resources (AETUF) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
AETUFPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
by Zacks Equity Research
Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United States till Feb. 25, 2035.
TEVAPositive Net Change HALOPositive Net Change CPRXNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bristol Myers Stock Gains 11.4% in a Year: Time to Buy or Sell?
by Ekta Bagri
Bristol Myers stock has performed well in the past year, gaining 11%. We believe there is more room for further growth, and any dip in the share price can be used as a buying opportunity.
BMYNegative Net Change PFENegative Net Change MRKPositive Net Change
biotechnology biotechs dividend-yield medical pharmaceuticals
FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief
by Zacks Equity Research
Pacira receives FDA approval for a new iovera Smart Tip aimed at expanding pain management capabilities to deeper nerves like the medial branch nerve.
HALOPositive Net Change PCRXNegative Net Change CTMXNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal
by Zacks Equity Research
Hoth stock soars as a mid-stage study meets the goal, showing significant improvement in skin toxicities related to EFGR inhibitor therapy in all HT-001-treated patients.
HALOPositive Net Change CTMXNegative Net Change HOTHNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Should You Buy Phreesia (PHR) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PHRNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Company News for Jan 8, 2025
by Zacks Equity Research
Companies In The News Are: RPM, LNN, TSLA, MRNA.
LNNNegative Net Change MRNANegative Net Change TSLANegative Net Change RPMNegative Net Change
auto-tires-trucks biotechnology construction industrial-products